MEASLES MUMPS AND RUBELLA VACCINE LIVE ATTENUATED (FREEZE-DRIED)

Dosage

Children: Refer to specific drug information for detailed dosage recommendations.

Adults: Refer to specific drug information for detailed dosage recommendations.

Mechanism of action

The mechanism of action varies depending on the specific drug that 'contains' certain active ingredients. Each compound will have its own unique pharmacological pathway and target within the body, which can include receptor modulation, enzyme inhibition, or other biochemical interactions.

Pharmacodynamics

Pharmacodynamics will depend on the active ingredients in the formulation. It generally encompasses the biochemical and physiological effects of the drug and its mechanisms of action, including the relationship between drug concentration and effect.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of the specific active ingredients within the formulation. This can vary significantly based on the drug's chemical properties, route of administration, and individual patient factors.

Pregnancy

Consult with a healthcare provider before use, as safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Generalized anxiety disorder
• Social anxiety disorder
• Panic disorder
• Off-label uses in depression
• Off-label uses in insomnia

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric populations.

Adults: Refer to specific clinical guidelines and individual patient factors to determine appropriate dosing. Consult relevant dosing references.

Mechanism of action

Less primarily acts as a selective serotonin reuptake inhibitor (SSRI), which increases levels of serotonin in the synaptic cleft by inhibiting its reabsorption into the presynaptic cell. This enhancement of serotonin neurotransmission is believed to contribute to its anxiolytic and antidepressant effects.

Pharmacodynamics

The pharmacodynamic effects of Less include its ability to elevate mood, reduce anxiety, and improve overall emotional well-being. It may also produce mild sedative effects, which can contribute to its use in anxiety and sleep disorders. The onset of action for anxiolytic effects generally occurs over several weeks, reflecting the need for sustained treatment to achieve therapeutic benefits.

Pharmacokinetics

Less is typically well-absorbed following oral administration with a bioavailability that is influenced by food. It undergoes extensive hepatic metabolism, primarily by cytochrome P450 enzymes, leading to various metabolites, some of which may have pharmacological activity. The elimination half-life is moderate, allowing for once-daily dosing in most cases. Renal excretion plays a significant role in the elimination of the drug and its metabolites.

Pregnancy

Safety during pregnancy has not been established. Use only if the benefit justifies the potential risk to the fetus.

Breast-feeding

Use with caution. It is not known if the drug is excreted in human milk.

Storage

Store in a cool, dry place, away from light and moisture.

Indications

• Prevention of measles through vaccination
• Management of measles infection in symptomatic patients
• Prevention of complications associated with measles infection

Dosage

Children: Refer to local vaccination guidelines for measles immunization recommendations.

Adults: Refer to local vaccination guidelines for measles immunization recommendations.

Mechanism of action

The measles virus enters host cells through the interaction of its hemagglutinin (H) protein with the CD150 (SLAM) receptor on the surface of immune cells. Following entry, the viral RNA is released into the cytoplasm, leading to the replication of the viral genome and the production of viral proteins. The newly formed virions are then released from the host cell, allowing the virus to spread to adjacent cells.

Pharmacodynamics

Measles virus infection leads to a robust immune response, resulting in the activation of both humoral and cellular immunity. The disease is characterized by an initial immune suppression, followed by a strong immune response that typically clears the virus. However, this immune suppression can leave the host vulnerable to secondary infections.

Pharmacokinetics

As a virus, measles does not have pharmacokinetic properties in the traditional sense, as it does not undergo metabolism or elimination like a drug. Instead, the virus's lifecycle involves attachment, entry, replication, and release from host cells. The duration of viral shedding can last for several days before the appearance of the rash.

Contra-indications

• Severe allergic reaction to a previous dose of measles vaccine
• Severe immunodeficiency (e.g., in patients with HIV/AIDS, or those receiving high-dose immunosuppressive therapy)
• Pregnancy (in certain live vaccines, including measles)

Adverse effects

• Fever
• Rash
• Diarrhea
• Otitis media
• Pneumonia
• Encephalitis (rare)

Interactions

• Live attenuated vaccines should not be administered simultaneously with immunoglobulins (e.g., anti-rabies serum) as they may interfere with the immune response
• Corticosteroids may reduce the immune response to the vaccine

Precautions

• Assess for history of severe allergic reactions
• Monitor for signs of respiratory distress in patients with a history of asthma or other respiratory conditions
• Consider vaccination timing in patients with recent blood transfusions or immunoglobulin administration

Pregnancy

Measles vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women should be advised to avoid pregnancy for a month after receiving the vaccine.

Breast-feeding

Measles vaccination is generally considered safe during breastfeeding, though it is recommended to consult healthcare providers for individual cases.

Storage

Store in a refrigerator at 2°C to 8°C, do not freeze. Protect from light.

Formulations

• Measles vaccine (live attenuated)
• Combination measles, mumps, rubella (MMR) vaccine

Indications

• Prevention of mumps through vaccination
• Management of mumps infection
• Monitoring for complications such as orchitis or meningitis

Dosage

Children: Refer to the BNF for Children for specific vaccination schedules and dosage recommendations related to the MMR vaccine.

Adults: Refer to the specific guidelines for vaccination, typically the MMR vaccine is administered as a two-dose series, with the first dose given at 1 year of age and a second dose at 4 to 6 years of age. Further details should be checked in the relevant vaccination schedule.

Mechanism of action

The mumps virus enters host cells by binding to sialic acid receptors on the surface of the cells. Once inside, the virus releases its RNA genome, leading to the production of viral proteins and replication of the viral genome. The newly formed viral particles are then released from the host cell, allowing for further infection of adjacent cells.

Pharmacodynamics

Mumps primarily affects the salivary glands but can also impact other organs such as the testes, ovaries, pancreas, and central nervous system. The immune response to the infection typically involves the activation of T cells and the production of antibodies, which help to clear the virus from the body. The severity of the disease can vary, with some individuals experiencing mild symptoms while others may develop complications such as orchitis or meningitis.

Pharmacokinetics

The pharmacokinetics of the mumps virus is not applicable in the traditional sense as it is a viral infection. However, the incubation period for mumps is typically 16 to 18 days, with the virus being contagious from approximately three days before to five days after the onset of parotitis. The immune response develops over a period of weeks, leading to long-lasting immunity in most cases post-infection or vaccination.

Adverse effects

• Fever
• Headache
• Muscle pain
• Swelling of the salivary glands
• Orchitis (inflammation of the testes)
• Oophoritis (inflammation of the ovaries)
• Meningitis
• Encephalitis

Precautions

• Individuals with weakened immune systems should be monitored closely.
• Vaccination may be less effective in those with specific conditions affecting the immune response.

Pregnancy

Mumps vaccination is generally avoided during pregnancy unless the benefits outweigh the risks, as the effects of the vaccine on fetal development are not fully established.

Breast-feeding

Vaccination is not contraindicated during breastfeeding, but consultation with a healthcare provider is recommended.

Storage

Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Formulations

• Live attenuated mumps virus vaccine

Indications

• Bacterial infections
• Viral infections
• Fungal infections
• Vaccination
• Rehydration therapy

Dosage

Children: Refer to the BNF for Children for appropriate dosing information based on the specific reconstituted medication and the child's age, weight, and clinical condition.

Adults: Refer to the specific product's prescribing information for detailed dosing guidelines. Doses vary depending on the drug being reconstituted and the condition being treated.

Mechanism of action

The mechanism of action for reconstituted drugs depends on the specific medication being reconstituted. For example, reconstituted antibiotics may work by inhibiting bacterial cell wall synthesis, disrupting protein synthesis, or interfering with nucleic acid metabolism. Each active ingredient will have its unique pathway that facilitates its therapeutic effect.

Pharmacodynamics

Pharmacodynamics refers to the study of the effects of drugs on biological systems. Reconstituted medications exhibit pharmacodynamic properties that are primarily dictated by their active ingredients. For antibiotics, this may involve bactericidal or bacteriostatic actions, determined by the drug's concentration and the susceptibility of the target bacteria. The onset of action, peak effect, and duration of action also vary based on the drug's formulation and the route of administration.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of drugs. Reconstituted medications are typically administered parenterally, which allows for rapid absorption into the bloodstream. The pharmacokinetics of the drug will depend on its specific formulation and the characteristics of the diluent used. Factors such as volume of reconstitution and the solubility of the active ingredient can influence the drug's bioavailability and clearance rates. Generally, reconstituted drugs follow first-order kinetics, where the rate of elimination is proportional to the drug concentration in the plasma.

Pregnancy

Consult relevant guidelines, as safety varies with specific drugs being reconstituted.

Breast-feeding

Consult relevant guidelines, as safety may vary based on the drug.

Storage

Store reconstituted solutions as per specific drug guidelines, typically in a cool, dry place, protected from light.

Indications

• Prevention of rubella infection through vaccination
• Screening and management of congenital rubella syndrome in newborns
• Public health measures to control rubella outbreaks

Dosage

Children: For vaccination, the MMR vaccine is typically administered to children at ages 12-15 months and a second dose at 4-6 years.

Adults: For vaccination, a single dose of the MMR (measles, mumps, rubella) vaccine is recommended for adults who have not been previously vaccinated or who lack immunity.

Mechanism of action

The rubella virus enters the body through the respiratory tract and replicates in the nasopharynx and regional lymph nodes. It then spreads to the bloodstream and other tissues, leading to a systemic infection. The immune response to the virus, including the production of IgM and IgG antibodies, is responsible for the clinical manifestations of the disease.

Pharmacodynamics

The rubella virus is a single-stranded RNA virus that belongs to the Togaviridae family. After infection, the virus induces an immune response that includes both humoral and cellular immunity. The resulting antibody production provides long-lasting immunity to reinfection. The clinical symptoms, such as fever and rash, are primarily due to the immune response rather than direct viral damage.

Pharmacokinetics

The incubation period for rubella is typically 14 to 21 days. The virus is present in the nasopharynx and urine. The immune response develops within a few days of infection, leading to the production of antibodies. The presence of IgM antibodies indicates an acute infection, while IgG antibodies indicate past infection or vaccination. The virus is usually eliminated from the body within a few weeks, but immunity persists for life following infection or vaccination.

Contra-indications

• Hypersensitivity to rubella vaccine components
• Pregnancy in women who have not been vaccinated or infected previously

Adverse effects

• Mild fever
• Rash
• Joint pain
• Lymphadenopathy
• Transient thrombocytopenia

Interactions

• Live attenuated vaccines may interfere with each other
• Immunosuppressive therapies may reduce vaccine efficacy

Precautions

• History of anaphylactic reactions to neomycin or gelatin
• Individuals with severe immunodeficiency should not receive live vaccines
• Pregnant women should avoid conception for at least one month after vaccination

Pregnancy

Rubella vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women are advised to receive the vaccine before conception.

Breast-feeding

Rubella vaccination is considered safe during breastfeeding.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Live attenuated rubella vaccine

Indications

• Severe bacterial infections
• Sepsis
• Pneumonia
• Urinary tract infections
• Intra-abdominal infections

Dosage

Children: Refer to established dosing guidelines and clinical protocols for specific dosing information, tailored to the child's age, weight, and renal function.

Adults: Refer to established dosing guidelines and clinical protocols for specific dosing information, as it varies based on the type and severity of the infection, renal function, and local guidelines.

Mechanism of action

Single acts by binding to the 30S ribosomal subunit of bacterial ribosomes, inhibiting protein synthesis. This binding interferes with the translation of mRNA, leading to the production of nonfunctional or toxic peptides, which ultimately results in bacterial cell death.

Pharmacodynamics

Single exhibits concentration-dependent killing, meaning that higher drug concentrations result in more effective bacterial killing. Its effects are also characterized by a post-antibiotic effect, where bacterial growth remains suppressed even after drug concentrations fall below the minimum inhibitory concentration (MIC). The drug's effectiveness is influenced by the rate of bacterial growth and susceptibility to the agent.

Pharmacokinetics

Single is usually administered intravenously or intramuscularly due to poor oral absorption. It distributes widely in body fluids and tissues, but it does not penetrate well into the central nervous system. The drug is primarily eliminated by the kidneys through glomerular filtration, and its half-life can be significantly prolonged in patients with renal impairment. Monitoring of serum drug levels is often necessary to avoid toxicity.

Pregnancy

Consult relevant guidelines. The safety of this drug during pregnancy has not been established.

Breast-feeding

Consult relevant guidelines. The safety of this drug during breastfeeding has not been established.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Pain management
• Inflammation
• Fever reduction

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing guidelines.

Adults: Refer to the latest clinical guidelines or specific product information for adult dosing recommendations.

Mechanism of action

Than may act by inhibiting the synthesis of prostaglandins, which are compounds involved in the inflammatory response and pain signaling. This mechanism typically involves the inhibition of cyclooxygenase (COX) enzymes, subsequently reducing the production of inflammatory mediators.

Pharmacodynamics

The pharmacodynamic effects of Than generally include analgesia (pain relief), anti-inflammatory effects, and antipyretic properties (fever reduction). Its efficacy in these areas can vary based on the condition being treated and the specific formulation of the drug.

Pharmacokinetics

Than is absorbed through the gastrointestinal tract, with peak plasma concentrations typically achieved within 1 to 2 hours after oral administration. It is metabolized primarily in the liver and excreted via the kidneys. The half-life can vary depending on the formulation and individual patient factors.

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare professional for advice.

Breast-feeding

Use with caution. Monitor infant for potential adverse effects. Consult a healthcare professional for advice.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Dosage

Children: Refer to specific medication guidelines for paediatric dosing, as volume alone does not dictate a standard dosage.

Adults: Refer to specific medication guidelines for adult dosing, as volume alone does not dictate a standard dosage.

Pregnancy

Volume is generally considered safe during pregnancy, but it is important to assess the individual needs and circumstances of the patient.

Breast-feeding

Volume can be used during breastfeeding, but caution is advised and it is recommended to consult with a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Moderate to severe pain
• Chronic pain management
• Postoperative pain control

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in paediatric populations.

Adults: Refer to relevant prescribing guidelines for adults, as specific dosing should be determined based on clinical circumstances and patient response.

Mechanism of action

When acts primarily on the mu-opioid receptors in the central nervous system. Upon binding to these receptors, it inhibits the release of neurotransmitters involved in the pain pathway, leading to an analgesic effect. This action alters the perception of pain and emotional response to pain, providing relief.

Pharmacodynamics

When produces its effects by activating opioid receptors, which are G-protein coupled receptors. This activation leads to the inhibition of adenylate cyclase, decreased intracellular cAMP, and the opening of potassium channels, resulting in hyperpolarization of neurons. The net effect is a decrease in neuronal excitability and reduced transmission of pain signals.

Pharmacokinetics

When is well absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It has a high protein binding capacity (approximately 90-95%), primarily to albumin. The drug undergoes extensive hepatic metabolism, primarily via the cytochrome P450 system, with a half-life of about 3 to 7 hours. Renal excretion accounts for the elimination of its metabolites, which may accumulate in patients with renal impairment.

Adverse effects

• Drowsiness
• Dizziness
• Nausea
• Dry mouth
• Constipation
• Blurred vision

Interactions

• CNS depressants may enhance sedative effects
• Alcohol may increase drowsiness
• Antihistamines may have additive effects

Precautions

• Use with caution in patients with a history of substance abuse
• Caution in elderly patients due to increased sensitivity to effects
• Monitor for signs of dependence or withdrawal

Pregnancy

Safety during pregnancy has not been established, use only if clearly needed.

Breast-feeding

Not recommended while breastfeeding due to potential effects on the infant.

Storage

Store at room temperature, away from moisture and heat.

Formulations

• Tablets
• Syrups
• Injectable forms